Related Experiment Video
Updated: Aug 14, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
A Case Report of Mixed Phenotype Acute Leukemia with Plasmacytoid Dendritic Cell Proliferation
Background:
The goal was to improve the understanding of mixed phenotypic acute leukemia (MPAL) complicated with plasmacytoid dendritic cell (PDC) proliferation.
Methods:
A case of mixed phenotype acute leukemia with plasmacytoid dendritic cell hyperplasia was reported. The clinical characteristics, treatment, and prognosis were analyzed by reviewing relevant literature.
Results:
The patient was a young female with clinical manifestations of splenomegaly and lymph node enlargement. The bone marrow smear showed hyperactive proliferation, 95% of protoblastic cells. The protoblastic cell body is large, more cell mass, stained gray blue, a small amount of azurophilicgranule can be seen in some cytoplasm, pseudopodia, drag tail, and other phenomena. The nucleus was twisted and folded. Chromatin is fine with nucleoli and Auer rods seen in the cytoplasm. Immune typing: Abnormal primordial cells accounted for 44.75%, and the primordial cells expressed both myeloid markers (CD33, CD13, MPO) and T-series markers (CD7, CD5, Ccd3), which were considered MPAL (M/T) according to WHO diagnostic criteria. In addition, a group of plasmoid dendritic cells occupied an increased proportion of 10.31% of nuclear cells. No obvious phenotypic abnormalities were observed. BCR/ABL fusion genes P190/P210 were negative. NRAS, NOTCH1, and DNMT3A mutations were detected by polymerase chain reaction. Combined with the above results, acute mixed cell leukemia (M/T) with plasmacytoid dendritic cell proliferation was diagnosed.
Conclusions:
The diagnosis of mixed phenotype acute leukemia with plasmacytoid dendritic cell proliferation needs to be integrated with clinical manifestations, cytomorphology, immunology, cytogenetics, and molecular biology, etc. Disease should be diagnosed and treated as early as possible.
Insights
This study reports a rare case of mixed phenotype acute leukemia with plasmacytoid dendritic cell proliferation. Early diagnosis and integrated analysis are crucial for effective treatment of this complex leukemia.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Mixed phenotype acute leukemia (MPAL) is a rare and aggressive hematologic malignancy.
- Understanding MPAL with concurrent plasmacytoid dendritic cell (PDC) proliferation is crucial for improved diagnostics and treatment strategies.
Observation:
- A case study of a young female presenting with splenomegaly and lymphadenopathy.
- Bone marrow examination revealed 95% blast cells with mixed myeloid and T-cell lineage markers (CD33, CD13, MPO, CD7, CD5, Ccd3), confirming MPAL (M/T) by WHO criteria.
- A significant proliferation of plasmacytoid dendritic cells (10.31%) was noted in the bone marrow without apparent phenotypic abnormalities.
Findings:
- The patient's MPAL (M/T) was characterized by abnormal blast morphology, including Auer rods.
- Immunophenotyping confirmed aberrant expression of both myeloid and T-cell markers on blast cells.
- Molecular analysis for BCR/ABL fusion genes was negative, while NRAS, NOTCH1, and DNMT3A mutations were detected.
Implications:
- Accurate diagnosis of MPAL with PDC proliferation requires a comprehensive approach integrating clinical, morphological, immunophenotypic, cytogenetic, and molecular data.
- Early diagnosis and prompt initiation of treatment are essential for improving patient outcomes in MPAL.
- This case highlights the importance of recognizing and characterizing rare hematologic malignancies for advancing clinical practice.
